Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment. Issue 11 (26th August 2022)

• Record Type: Journal Article
• Authors: Ochiai, Ryosuke; Hayashi, Kentaro; Yamamoto, Hiroshi; Fujii, Risa; Saichi, Naomi; Shinchi, Hiroki; Ishida, Tsuyoshi; Honda, Takeshi; Shimizu, Tetsuo; Matsutani, Noriyuki; Seki, Nobuhiko; Kawamura, Masafumi; Ueda, Koji
• Is Part Of: Cancer science. Volume 113:Issue 11(2022)
• Page Start: 3960
• Page End: 3971
• Publication Date: 2022-08-26
• Subjects: DOK3 -- exosome -- gefitinib -- non–small‐cell lung cancer -- proteomics; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15512
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: To identify liquid biomarkers that predict clinical outcomes of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), we enrolled patients with EGFR gene mutation‐positive non–small‐cell lung cancer who were intended to receive gefitinib treatment. Using plasma samples obtained prior to gefitinib treatment from 12 enrolled patients, we performed comprehensive proteomic analysis of plasma exosomes to explore proteins correlating with tumor reduction rate (TRR), progression‐free survival (PFS), or overall survival (OS). Of the detected 1769 proteins, 119, 130, or 119 proteins demonstrated a strong correlation (|r| > 0.5) with TRR, PFS, or OS, respectively. Interestingly, 34 (29%), 41 (32%), or 27 (23%) of them, respectively, were functionally involved in the regulation of the immune response. CD8α chain was consistently listed as a molecule positively correlated with PFS and OS, suggesting that the long‐lasting effects of gefitinib may be due to the antitumor effects of CD8 + T cells, as well as the induction of immunogenic apoptosis of tumor cells by blocking the EGFR signaling pathway. Notably, Doking Protein 3 (DOK3), a molecule involved in B‐cell receptor signaling, and some immunoglobulin and complement molecules exhibited a clear correlation with PFS longevity of gefitinib treatment. Indeed, the strong expression of DOK3 in B cells was confirmed within tertiary lymphoid structures of lung cancer tissues derived from patients with long PFS. These findings suggest that the patients with active B‐cell and T‐cell immunity as a host immunological feature are more likely to benefit from gefitinib therapy. Circulating exosomal DOK3 has the potential as a predictive marker of response to gefitinib indicating this immunological feature. Abstract : DOK3+ B cells in tertiary lymphoid structures (TLS) of lung cancer tissues and DOK3 levels in plasma exosomes showed clear correlation with both PFS and OS of gefitinib treatment.